Format

Send to

Choose Destination
Cancer. 2017 Jul 15;123(14):2698-2704. doi: 10.1002/cncr.30634. Epub 2017 Apr 3.

Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.

Author information

1
Chronic Disease Epidemiology Department, Yale School of Public Health, New Haven, Connecticut.
2
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
3
Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut.

Abstract

BACKGROUND:

Few studies have prospectively examined the relationship between vitamin D status and prostate cancer risk in black men, a group at high risk for both low vitamin D status and prostate cancer.

METHODS:

Among black men in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, we identified 226 prostate cancer cases and 452 controls matched on age at randomization (±5 years), date of blood draw (±30 days), calendar year of cohort entry, and time since baseline prostate cancer screening (±1 year). Conditional logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between serum 25-hydroxyvitamin D [25(OH)D], vitamin D binding protein (DBP), the 25(OH)D:DBP molar ratio, and prostate cancer risk.

RESULTS:

Serum 25(OH)D was not associated with overall prostate cancer (Q4 vs Q1: OR, 0.73; 95% CI, 0.40-1.33; P for trend = .25), although there were apparent inverse associations for nonaggressive disease (global P = .03, clinical stage I/II, and Gleason score <7) and among men ≥62 years old (P for interaction = .04) that were restricted to Q3. Interestingly, serum DBP was significantly inversely associated with prostate cancer risk (Q4 vs Q1: OR, 0.45; 95% CI, 0.20-1.00; P for trend = .03), whereas the 25(OH)D:DBP molar ratio was not. Results were similar when we mutually adjusted for 25(OH)D and DBP, and we found no evidence of interaction between the two.

CONCLUSION:

Our study suggests higher (versus lower) circulating DBP may be independently associated with a decreased prostate cancer risk in black men independent of 25(OH)D status. Cancer 2017;123:2698-704. © 2017 American Cancer Society.

KEYWORDS:

25-hydroxyvitamin D; African American/black men; prostate cancer; racial/ethnic cancer disparities; vitamin D binding protein

PMID:
28369777
PMCID:
PMC5498231
DOI:
10.1002/cncr.30634
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center